The article says SpaceX’s upcoming IPO will add to a growing set of public companies tied to the space economy. It cites renewed focus on U.S.-China lunar efforts and SpaceX’s Mars plans and “Golden Dome” missile-shield plans. It lists competitors across launch, satellites, imagery, and defense, noting SpaceX had 80%+ of global launches last year and 10,000+ Starlink satellites in orbit.
Voyager Therapeutics Inc (VGYR) has seen a modest 30% rise in its stock over the past year, but analysts predict a potential 250% surge in the next 12 months due to advancements in its drug programs. The company recently presented positive preclinical data for its Alzheimer's disease gene therapy, VY1706, which reduced tau protein in non-human primates by up to 64% without adverse events. Voyager plans to seek FDA authorization for human clinical trials of VY1706 in Q2 2026 and expects efficacy data for its VY7523 anti-tau antibody program in the latter half of the year.
Voyager Therapeutics Inc. announced that its CFO, Nathan Jorgensen, will resign from his position, effective May 8, 2026. The announcement was made via a brief news item from Refinitiv.
